Comparison of Epstein–Barr virus‐positive mucocutaneous ulcer associated with treated lymphoma or methotrexate in Japan

Daroontum, Teerada; Kohno, Kei; Eladl, Ahmed E.; Satou, Akira; Sakakibara, Ayako; Matsukage, Shoichi; Yakushiji, Naoki; Ya-In, Charin; Nakamura, Shigeo; Asano, Naoki; Kato, Seiichi

doi:10.1111/his.13464

Cited by 44 publications

(39 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…22 The ulcer mostly occurs in elderly patients at a median age of 66.4 years (range, 16-101 years) and exhibits a female predominance. [22][23][24] Patients usually present with a solitary, painful ulcer unassociated with hepatic, splenic, systemic lymph node, or bone marrow involvement, although regional lymph node involvement and multifocality (17% of the cases) have been described. 21,22,25 The blood viral load is negative in almost all cases.…”

Section: Ebv þ Mucocutaneus Ulcermentioning

confidence: 99%

“…21 In the gastrointestinal (GI) tract, the ulcer can affect any organ. 21,23 The clinical symptoms vary and include hemorrhage, diarrhea, and perianal skin ulceration, a clinical mimicker of inflammatory bowel disease (IBD). When involving the colon, the ulcers exhibit the same cellular infiltrate that permeates between unremarkable crypts.…”

Section: Ebv þ Mucocutaneus Ulcermentioning

confidence: 99%

“…None of those cases occurred in a setting of agerelated immunosenescence. 21,23,25,27,28 It appears that mucosal injury in IBD can facilitate infected B-cell replication and the development of EBVMCU. 29 At first glance, EBV may appear to represent a superimposed infection in patients with IBD.…”

Section: Ebv þ Mucocutaneus Ulcermentioning

confidence: 99%

“…22,25 Rare cases have progressed into HL, 27 whereas in posttransplant patients, relapses with other more aggressive posttransplant lymphoproliferative diseases have been reported. 23 Only one disease-associated death has been reported. 26…”

Section: Ebv þ Mucocutaneus Ulcermentioning

confidence: 99%

See 3 more Smart Citations

Select Epstein-Barr Virus–Associated Digestive Tract Lesions for the Practicing Pathologist

Alruwaii

Montgomery

2020

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— Epstein-Barr virus is a ubiquitous oncogenic virus. During the past 5 decades, the virus has been linked to several disease entities, both neoplastic and nonneoplastic. Several Epstein-Barr virus–associated conditions affect the digestive organs, ranging from mild transient inflammatory conditions to more debilitating and even fatal diseases. Objective.— To discuss the clinicopathologic aspects of some newly or recently recognized Epstein-Barr virus–related conditions encountered in the digestive system and their therapeutic implications. Data Sources.— Published peer-reviewed literature was reviewed. Conclusions.— This article highlights the importance of recognizing the discussed lesions because they influence the direct clinical management or work as a potential predictive marker for therapy.

show abstract

Section: Ebv þ Mucocutaneus Ulcermentioning

confidence: 99%

Section: Ebv þ Mucocutaneus Ulcermentioning

confidence: 99%

Section: Ebv þ Mucocutaneus Ulcermentioning

confidence: 99%

Section: Ebv þ Mucocutaneus Ulcermentioning

confidence: 99%

See 2 more Smart Citations

Select Epstein-Barr Virus–Associated Digestive Tract Lesions for the Practicing Pathologist

Alruwaii

Montgomery

2020

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…Longterm effects of other profound insults to the immune system, such as history of chemotherapy, are still poorly understood, but they may also predispose patients to potentially self-resolving EBVassociated B-cell lymphoproliferations similar to those in other iatrogenic immunodeficiency settings. 41,42 Manifestations of primary immunodeficiency vary markedly and are beyond the scope of this perspective; in addition to susceptibility to infection, there may be immune dysregulation, including autoimmune phenomena, and predilection to hemophagocytic lymphocytosis. 43 Among patients with common variable immunodeficiency, those with autoimmune cytopenias are at increased risk for LPDs.…”

Section: When To Suspect Underlying Immunodeficiencymentioning

confidence: 99%

Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?

Natkunam

Gratzinger

Chadburn

et al. 2018

Blood

View full text Add to dashboard Cite

Immunodeficiency-associated lymphoproliferative disorders (IA-LPDs) are pathologically and clinically heterogeneous. In many instances, similar features are shared by a spectrum of IA-LPDs in clinically diverse settings. However, the World Health Organization (WHO) classifies IA-LPDs by their immunodeficiency setting largely according to the paradigm of posttransplant lymphoproliferative disorders but with inconsistent terminology and disease definitions. The field currently lacks standardization and would greatly benefit from thinking across immunodeficiency categories by adopting a common working vocabulary to better understand these disorders and guide clinical management. We propose a 3-part unifying nomenclature that includes the name of the lesion, associated virus, and the specific immunodeficiency setting for all IA-LPDs. B-cell lymphoproliferative disorders (LPDs) are usually Epstein-Barr virus (EBV)+ and show a spectrum of lesions, including hyperplasias, polymorphic LPDs, aggressive lymphomas, and, rarely, indolent lymphomas. Human herpes virus 8–associated LPDs also include polyclonal and monoclonal proliferations. EBV− B-cell LPDs and T- and NK-cell LPDs are rare and less well characterized. Recognition of any immunodeficiency is important because it impacts the choice of treatment options. There is an urgent need for reappraisal of IA-LPDs because a common framework will facilitate meaningful biological insights and pave the way for future work in the field.

show abstract

Cutaneous B‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management

2023

View full text Add to dashboard Cite

Disease Overview Approximately one‐fourth of primary cutaneous lymphomas are B‐cell derived and are generally classified into three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL, LT). Diagnosis Diagnosis and disease classification is based on histopathologic review and immunohistochemical staining of an appropriate skin biopsy. Pathologic review and an appropriate staging evaluation are necessary to distinguish primary cutaneous B‐cell lymphomas from systemic B‐cell lymphomas with secondary skin involvement. Risk‐Stratification Disease histopathology remains the most important prognostic determinant in primary cutaneous B‐cell lymphomas. Both PCFCL and PCMZL are indolent lymphomas that infrequently disseminate to extracutaneous sites and are associated with 5‐year survival rates that exceed 95%. In contrast, PCDLBCL, LT is an aggressive lymphoma with an inferior prognosis. Risk‐Adapted Therapy PCFCL and PCMZL patients with solitary or relatively few skin lesions may be effectively managed with local radiation therapy. While single‐agent rituximab may be employed for patients with more widespread skin involvement, multiagent chemotherapy is rarely appropriate. In contrast, management of patients with PCDLBCL, LT is comparable to the management of patients with systemic DLBCL.

show abstract

Comparison of Epstein–Barr virus‐positive mucocutaneous ulcer associated with treated lymphoma or methotrexate in Japan

Abstract: Treated lymphoma-associated EBVMCU, which is an indolent and self-limited condition, must be recognised to avoid misdiagnosing it as a relapse of malignant lymphoma during treatment.

Cited by 44 publications

References 37 publications

Select Epstein-Barr Virus–Associated Digestive Tract Lesions for the Practicing Pathologist

Select Epstein-Barr Virus–Associated Digestive Tract Lesions for the Practicing Pathologist

Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?

Cutaneous B‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management

Contact Info

Product

Resources

About